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IBDVa b s t r a c t
Different immunogens such as subunit, DNA or live viral-vectored vaccines against Infectious Bursal
Disease virus (IBDV) have been evaluated in the last years. However, the heterologous prime-boost
approach using recombinant modified vaccinia Ankara virus (rMVA), which has shown promising results
in both mammals and chickens, has not been tried against this pathogen yet. IBD is a highly contagious
and immunosuppressive disease of poultry that affects mainly young chicks. It is caused by IBDV, a
double-stranded RNA virus carrying its main antigenic epitopes on the capsid protein VP2. Our objective
was to evaluate the immune response elicited by two heterologous prime-boost schemes combining an
rMVA carrying the VP2 mature gene (rVP2) and a recombinant VP2 protein produced in Nicotiana ben-
thamiana (pVP2), and to compare them with the performance of the homologous pVP2-pVP2 scheme
usually used in our laboratory. The SPF chickens immunized with the three evaluated schemes elicited
significantly higher anti-VP2 antibody titers (p < 0.001) and seroneutralizing titers (p < 0.05) and had less
T-cell infiltration (p < 0.001), histological damage (p < 0.001) and IBDV particles (p < 0.001) in their bur-
sae of Fabricius when compared with control groups. No significant differences were found between both
heterologous schemes and the homologous one. However, the rVP2-pVP2 scheme showed significantly
higher anti-VP2 antibody titers than pVP2-rVP2 and a similar tendency was found in the seroneutraliza-
tion assay. Conversely, pVP2-rVP2 had the best performance when evaluated through bursal parameters
despite having a less potent humoral immune response. These findings suggest that the order in which
rVP2 and pVP2 are combined can influence the immune response obtained. Besides, the lack of a strong
humoral immune response did not lessen the ability to protect from IBDV challenge. Therefore, further
research is needed to evaluate the mechanisms by which these immunogens are working in order to
define the combination that performs better against IBDV.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Infectious Bursal Disease (IBD) is a highly contagious and
immunosuppressive disease of poultry that affects mainly young
chicks [1]. It is caused by the Infectious Bursal Disease Virus(IBDV), a bi-segmented double-stranded RNA virus [2] carrying
its main antigenic epitopes on the capsid protein VP2 [3]. This viral
pathogen targets IgM bearing B-lymphocytes in the bursa of Fabri-
cius (BF) [4]. The economic losses caused by IBDV are due to
increased susceptibility to other pathogens and poor vaccine effi-
cacy because of the immunosuppression acquired by the animals,
but can also be caused by high mortality in flocks infected with
very virulent IBDV strains [5].
IBD is essentially controlled through vaccination. Vaccines
against IBDV should be given relatively early because of the chick-
en’s susceptibility period to the disease. At present, the most
widely used immunogens are based on live attenuated IBDV
Table 1
Experimental design.
Group 1st inoculation 2nd inoculation Challenge
1 pVP2 (8 lg) pVP2 (8 lg)
8.25  106 PFU/
chicken
2 rVP2 (6.5  105
PFU)
pVP2 (8 lg)
3 pVP2 (8 lg) rVP2 (6.5  105
PFU)
4 rGFP (6.5  105
PFU)
rGFP (6.5  105
PFU)
5 pGFP (8 lg) pGFP (8 lg)
Six specific pathogen free chickens were used in each group. Inoculations were
performed at 14 days post hatch (1st) and 28 days post hatch (2nd). Animals were
challenged three weeks after the 2nd inoculation and euthanized 5 days post
challenge.
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sal atrophy, and are effective only when IBDV maternal antibodies
have decreased [6].
In order to overcome these issues, different immunogens such
as subunit, DNA or live viral-vectored vaccines have been ration-
ally designed and evaluated [6,7]. Our group has had successful
experiences immunizing chickens with VP2 protein produced both
in Nicotiana benthamiana plants [8] and through non replicative
poxviral vectors [9–11].
To induce broader immune responses, different heterologous
prime-boost regimes have been successfully used in mammals
[12]. Particularly, recombinant modified vaccinia Ankara virus
(rMVA) has shown to be more effective when used as a heterolo-
gous boost after priming with the same antigen in a different form
[13], both in mammal [14,15] and avian [16] models. On the other
hand, a poxvirus prime-protein boost scheme has been considered
the most successful vaccination protocol against HIV-1 [17].
Thus, having a consistently immunogenic protein as VP2 from
N. benthamiana (pVP2), our objective was to investigate whether
its combination with a recombinant MVA expressing VP2 (rVP2)
in a heterologous prime-boost scheme could elicit a stronger
immune response than the one induced by the homologous
scheme based on pVP2. This is, to the best of our knowledge, the
first trial combining a recombinant MVA with a recombinant pro-
tein as a strategy against IBDV in chickens.2. Materials and methods
2.1. Animals
Specific pathogen free (SPF) embryonated eggs were purchased
from Instituto Rosenbusch S.A. (Argentina) and hatched in an auto-
matic incubator (Yonar, Argentina). Chickens were housed in indi-
vidual cages with food and water provision ad libitum. All
procedures involving the use of animals were performed in agree-
ment with institutional guidelines and approved by the Institu-
tional Committee for the Care and Use of Experimental Animals
(CICUAE – CICVyA – INTA).2.2. Immunogens
Recombinant MVA viruses have been previously obtained in our
laboratory: rVP2 [9] and MVA-GFP (rGFP) carry the coding
sequence of IBDV-VP2 mature protein or the gene coding for the
green fluorescent protein (GFP), respectively.
MVA viruses were amplified in primary Chicken Embryo Fibrob-
lasts (CEFs) cultured in Dulbecco’s Modified Eagle Medium (D-
MEM) (Thermo Fisher Scientific, USA) supplemented with 2% fetal
bovine serum (Internegocios, Argentina) at 37 C with 5% of CO2.
When 90–100% cytopathic effect (CPE) was detected, cells and
supernatant were collected together and 3 freeze-thaw cycles were
performed to release the virus.
The other antigen, pVP2, which also had its GFP-control (pGFP),
was extracted from pEAQ vector-infiltrated leaves [18] in a blender
with 3 volumes of chilled buffer containing phosphate buffered
saline (PBS) pH 7.3, complete EDTA-free protease inhibition cock-
tail tablets (Roche, Germany) and 0.04% antifoam O-30 (Sigma
Aldrich, USA), and the expression of VP2 was evaluated through
Western Blot as described in [8].2.3. Experimental design
Thirty chicks were randomly divided in 5 groups and immu-
nized intramuscularly (IM) as stated in Table 1. Chickens were bledperiodically by the wing vein, and the sera obtained were stored at
20 C until use.
Three weeks after the boost immunization animals were chal-
lenged orally with 8.25  106 PFU of Winterfield strain of IBDV
and euthanized five days post challenge.2.4. Anti-IBDV and anti-VP2 antibodies detection
Sera obtained before challenge were analyzed using the IDEXX
IBD test kit (IDEXX Laboratories, USA) following manufacturer’s
instructions.
In addition, sera were tested for specific anti-VP2 antibodies
using an indirect ELISA based on subviral particles (SVP) formed
by IBDV VP2. Briefly, 96-well MaxisorpTM NuncTM flat-bottom plates
(Thermo Scientific, USA) were coated with 25 ng of SVPs perwell in
0.1 M carbonate-bicarbonate buffer, pH 9.6, overnight at 4 C. After
blocking with 4% skimmilk in PBS–T (0.05% Tween 20), plates were
subsequently incubated with 3-fold serial dilutions of sample sera,
and 1/3000 dilutions of goat anti-chicken IgG antibodies coupled to
horseradish peroxidase (Bethyl Laboratories, USA). Revealing step
was performed using ABTS substrate (Sigma-Aldrich, USA)-H2O2
in citric acid buffer, pH 5. Reading was done at 405 nm after
20 min of incubation. Antibody titers were calculated as the
inverse of the highest dilution with an OD405nm value above the
mean +3.5 SD of the negative control groups.2.5. Seroneutralization assay
Sera were inactivated at 56 C for 30 min and twofold serially
diluted from 1/4 to 1/8192 in D-MEM. Dilutions were incubated
with 100 TCID₅₀ of Winterfield strain of IBDV for 1 h at 37 C in
96-well plates (Greiner bio-one, Germany). After that, 100 ll of a
cell suspension of 1.5  106 CEFs/ml were added to each well.
The cell suspension was prepared in D-MEM supplemented with
4% fetal bovine serum (FBS), 25 mM HEPES and a mixture of antibi-
otic/antimycotic (Gibco, USA). Cells were cultured at 37 C with
5% CO₂ for 4 days, when CPE was observed. Seroneutralizing anti-
body (SN) titers were calculated as the inverse of the highest dilu-
tion showing no CPE.2.6. Lymphocyte isolation and flow cytometry analysis
Lymphocytes were isolated from the BF as previously described
[19]. Monoclonal antibodies (mAbs) (CD3-SPRD, CD4-PE, CD8a-
FITC) from Southern Biotech (Birmingham, USA) were employed.
Cell suspensions were analyzed with a BD FACSCalibur Flow
Cytometer (BD Biosciences, USA) and CellQuest software. The lym-
phocyte gate was defined by the forward/side scatter characteris-
tics of the cells and 30,000 events were analyzed.
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unchallenged SPF chickens were used for normalization of the val-
ues of all experimental groups.
2.7. Histopathological analysis of the bursae
Bursal samples were placed in 10% neutral buffered formalin
and paraffin embedded. Sections of BF were stained with haema-
toxylin and eosin following standard histological procedures and
they were microscopically examined for the presence of bursal
lesions under light microscopy. The scoring scale of histological
damage is shown in Table 2.
2.8. IBDV isolation in CEFs
Viral isolation assays were performed using pieces of bursa that
had been kept at 70 C. They were mechanically disrupted in PBS
and 3 frost/thaw cycles were performed. Homogenates were ten-
fold serially diluted and used to infect monolayers of CEFs seeded
in 96-well plates as described in the seroneutralization assay. After
4 days at 37 C, presence of CPE was determined. Viral titers were
expressed as TCID50/gr, using the Reed and Muench method [20].
2.9. Statistical analysis
Statistical analysis was done with GraphPad Prism Software
version 5.01. Means were compared using one-way ANOVA fol-
lowed by multiple rank comparisons with Tukey’s test. A probabil-
ity (p) value of 60.05 was considered statistically significant.
3. Results
3.1. Measurement of anti-IBDV and anti-VP2 humoral immune
response
Results of the analysis of serum samples are listed in Table 2.
Considering the manufacturer’s cut-off point, the homologous
pVP2 scheme induced the most consistent humoral immune
response as all chickens immunized with this regime elicited anti-
body titers above the mentioned point. In regard to heterologous
schemes, 5 over 6 chickens immunized with rVP2/pVP2 and 2
out of 6 animals receiving pVP2/rVP2 were positive for the test.
All the chickens in both control groups were negative. The progres-
sion of antibody titers over time is shown in Supplementary Fig. 1.
When testing the sera for specific anti-VP2 antibodies (Fig. 1),
all chickens immunized with either homologous or heterologous
VP2 schemes had significantly higher antibody titers than both
control groups (p < 0.001). Although none of the heterologousTable 2
Anti-IBDV antibodies, bursal damage and viral load.
Groups IBD AbA Histopathological BF lesionsB
Score 1 Score 2 Score 3
pVP2 6/6 3 3 0
rVP2/pVP2 5/6 3 3 0
pVP2/rVP2 2/6 6 0 0
rGFP 0/6 0 0 2
pGFP 0/6 0 0 3
A IDEXX IBD results consider the cut-off point indicated by the manufacturer (396). Pro
animals in each group (n = 6).
B Values indicate the number of chickens classified with certain histopathological scor
(LD) in bursal follicles and intraepithelial cystic formation (CF). Score 3: 30–70% of LD an
and/or fibrotic changes. The mean bursal score ± SD of each group is also shown. a,bDiffe
C The viral load is expressed as the mean ± SD of the viral titers of each group, whi
1.26 ⁄ 103 TCID50/gr were considered negative for this test. Different letters along the
p < 0.05 forb/c).schemes were significantly different compared to the homologous
pVP2 scheme, the group receiving rVP2/pVP2 had a significantly
higher antibody titer than the one vaccinated with pVP2/rVP2
(p < 0.05). These results demonstrated that homologous or heterol-
ogous prime-boost immunization schemes were able to induce an
IBDV specific humoral response. Besides, this immune response
was influenced by the order in which rVP2 and pVP2 were inocu-
lated in heterologous vaccination schemes.
3.2. Assessment of antibody neutralizing ability
To determine if the antibodies produced were capable of neu-
tralizing the virus, a seroneutralization assay was performed. In
this experiment, all groups immunized with schemes including
VP2 were able to elicit significantly higher SN titers than both con-
trol groups (Fig. 2). While there were no significant differences
between titers from homologous and heterologous VP2-schemes,
the median SN titer of the group immunized twice with pVP2
was considerably higher than the ones from both heterologous
schemes.
3.3. Evaluation of T cell infiltration in the BF after challenge
Increased infiltration of T lymphocytes into the BF has been
associated with IBDV infection and replication in such organ
[19,21]. Hence, the level of T cell infiltration in the bursa after chal-
lenge with IBDV can be taken as a parameter of vaccine protective
efficacy. In this context, we analyzed the percentage of T CD3+
CD4+ and CD3+ CD8+ cells (Fig. 3) in the bursa of chickens chal-
lenged with a high dose of Winterfield strain of IBDV.
Regardless of the VP2-scheme received, all groups inoculated
with this antigen had significantly less infiltration of T cells –both
CD4+ and CD8+ – in their bursae than both control groups
(p < 0.001). However, no significant differences were found
between neither homologous vs. heterologous nor between
heterologous schemes, showing that all VP2-schemes were effec-
tive to decrease T cell infiltration in BF.
3.4. Analysis of morphopathological changes in the bursae
The analysis of microscopic lesions produced by IBDV replica-
tion in the BF is a valid tool for measuring the infection severity
in chickens [22]. Microscopic alterations include lymphoid necro-
sis, formation of cystic cavities, infiltration of heterophils and fibro-
sis [23]. Thus, a histopathological analysis was made to search for
evidence of IBDV replication in chickens’ bursae.
Histopathological scoring results are presented in Table 2.
In agreement with the other results, all VP2-immunizedIBDV viral load (TCID50/gr)C
Score 4 Mean score ± SD
0 1.5 ± 0.5a <1.26 ⁄ 103//a
0 1.5 ± 0.5a <1.26 ⁄ 103//a
0 1.0a <1.26 ⁄ 103//a
4 3.67 ± 0.5b 4.08 ± 1.1 ⁄ 105//b
3 3.5 ± 0.5b 2.6 ± 1.53 ⁄ 105//c
portions shown represent the number of positive chickens over the total number of
e in each group. Score 1: unremarkable. Score 2: up to 30% of lymphocyte depletion
d intrafollicular CF. Score 4: >70% of lymphocyte depletion, with follicular necrotic
rent letters along the scores indicate significant differences (p < 0.001).
ch were calculated as described by Reed & Muench [20]. Chickens with less than
values indicate significant differences between treatments (p < 0.001 fora/b-c and
Fig. 1. Anti-VP2 antibody values evaluated through indirect ELISA. Sera from all
chickens were tested just before challenge with IBDV. The antibody titers were
Log10-transformed prior to analysis. Each column represents the mean value ± SD
of the corresponding group. a,b,cDifferent letters above bars indicate significant
differences among treatments (p < 0.05).
Fig. 2. Anti-IBDV neutralizing antibodies. A seroneutralization (SN) test was
performed over the sera obtained just before challenge. The graph shows the
median SN titer of each group (line inside the box) as well as the range of SN titers
elicited. Asterisks above the boxes indicate significant differences between groups
immunized with VP2 and both control groups (***p < 0.001 and *p < 0.05).
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GFP-immunized animals (p < 0.001), indicating that VP2 antigen
prevented histological damage. Although no significant differences
were found between the schemes with IBDV antigen, animals that
received pVP2 as a prime and rVP2 as a boost were completely and
homogeneously protected, whereas groups immunized with the
inverse heterologous or the homologous pVP2 schemes had up to
50% of their animals showing higher degree of pathological
changes.
Images of the morphopathological changes in the bursae are
included in Fig. 4.
3.5. Quantification of IBDV viral load in BF
The quantity of IBDV in BF after challenge can be used as an
indicator of the protective efficacy of an experimental immunogen.
In our experiment, results showed significantly higher IBDV titers
in both control groups (p < 0.001) compared to all groups immu-
nized with either homologous or heterologous VP2 schemes(Table 2). Although there were no differences among the three
evaluated immunization schemes, approximately 200-fold and
300-fold reductions of IBDV titer in BF were observed when com-
paring them with pGFP-group and rGFP-group, respectively.4. Discussion
The use of heterologous prime-boost schemes has been widely
explored in the last two decades. The key principles to support this
rationale are the ability to elicit both humoral and cell-mediated
immune responses and the avoidance of anti-vector immunity
issues [12,24]. Recombinant poxviruses have been extensively
tested in heterologous schemes and their effectiveness is the rea-
son by which these vaccine vectors are currently among the most
interesting candidates for HIV vaccines [25]. In mammals, recom-
binant MVA has been widely used as a booster in this kind of
immunization protocols [26], showing better results when admin-
istered in that order [13]. Priming with DNA vaccines and boosting
with non-replicative viral vectors has shown to be very effective to
induce strong cell-mediated immunity [27]. On the other hand,
either in mammals or chickens, proteic antigens are regarded as
preferential stimulators of the humoral immune response and,
thus, expected to elicit higher levels of antibodies than DNA or
viral-vectored vaccines.
Successful experiences with heterologous prime-boost also
exist in the avian model: DNA prime-inactivated vaccine boost
[28–31], DNA prime-protein boost [32], recombinant Fowlpox
prime-inactivated vaccine boost [33] and recombinant Adenovirus
prime-recombinant MVA boost [16] have all shown to be more
immunogenic when compared to homologous schemes.
In this context, we investigated: (a) whether a heterologous
prime-boost immunization with a subunit VP2 vaccine and a
recombinant MVA-VP2 could offer a higher anti-IBDV protective
efficacy than the homologous prime-boost with the subunit VP2
and, (b) if the order in which immunogens were given could affect
the immune response obtained.
As a general parameter of immunogenicity, anti-IBDV antibody
titers were evaluated. In this assay, all the homologous pVP2
immunized animals were positive, whereas 5/6 animals immu-
nized with rVP2/pVP2 scheme and 2/6 receiving the inverse
heterologous scheme were positive. A more specific anti-VP2
response was then evaluated, showing significantly better results
in rVP2/pVP2 immunized animals compared to those chickens
receiving the inverse sequence of antigens. Although none of the
heterologous schemes were significantly different from the homol-
ogous one, here we had the first evidence that the order of admin-
istration of the different antigens might be important.
In agreement with previous reports, pVP2 elicited high SN titers
[8]. In contrast, repeated immunizations with rVP2 had not
resulted in a strong humoral response [9] and, thus, it was possible
that the combination of both immunogens elicited less SN antibod-
ies than the homologous pVP2 scheme. However, when comparing
heterologous schemes there was a tendency towards a better per-
formance of rVP2/pVP2 over the inverse one. Altogether, these
findings suggest that the order in which both immunogens are
combined can affect the humoral immune response obtained.
Gao and coworkers [32] have reported that a protein boost after
a DNA priming resulted in the highest anti-IBDV humoral response,
and other researchers have reported similar results using DNA
prime-inactivated vaccine boost [28] or viral vectored prime-
inactivated vaccine boost [33]. Therefore, the rationale behind
priming with a vectored antigen and boosting with a proteic one
makes sense if what is sought is a strong humoral response while
also stimulating cell-mediated immunity. As an additional advan-
tage, it has been suggested that the smaller amount of antigen pro-
Fig. 3. Infiltration of T lymphocytes in the bursa of Fabricius after IBDV challenge. Chickens were challenged with Winterfield strain of IBDV and euthanized 5 days post
challenge. T-cell subpopulations present in BF were stained with specific antibodies and analyzed by flow cytometry. All individual values were normalized with the mean
percentage of each T-cell subtype obtained from healthy birds and then analyzed. Graphs show the mean fold-increase ± SD of the percentages of (A) T CD3+ CD4+ and (B)
CD3+ CD8+ cells in each group. Different letters over the bars indicate significant differences among treatments (p < 0.001 fora/b-c; p < 0.05 forb/c).
Fig. 4. Morphopathological changes of the bursae after IBDV challenge. An evaluation of pathological changes in the bursae was done at 5 days post challenge with the
Winterfield strain of IBDV. The left panel shows H&E stained sections of bursae with score 1 (A), 2 (B), 3 (C) and 4 (D) in a 10 magnification. The arrows point to
characteristic pathological changes as intraepithelial cysts and low degree of follicle lymphoid depletion primarily in the medullar area of follicles (B), high degree of
lymphoid depletion affecting even the cortex of the follicles (C) and severe lymphoid depletion in many follicles (D). The right panel shows representative macroscopical
pictures of bursae with score 1 (E), 2 (F), 3 (G) and 4 (H). A progression from rosy to a yellowish color can be seen. Also, an increment of haemorrhagic and edematous changes
are observed within high-scoring bursae.
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select for higher avidity in the antibodies produced [34].
Although neutralizing antibodies have been considered the
most relevant tool to protect against IBDV infection, recent studies
have raised doubt about the degree of dependence on them [35].
Some findings of our study support the hypothesis about the need
of a more balanced immune response. When merging the results
obtained in the analyses made on the bursae, we found that all
the VP2-vaccinated animals had significantly less infiltration of
T-cells (p < 0.001), IBDV viral loads (p < 0.001) and lower
histopathological mean scores (p < 0.001) than the control groups.
These results suggest that the three evaluated alternatives wereable to prevent IBDV from reaching the BF or to enhance viral
clearance from the affected tissue. However, an interesting finding
of this study is that, despite not being significantly different, the
histopathological scores were slightly better in the group primed
with pVP2 and boosted with rVP2. This contrasts with the results
of the humoral evaluation, although is consistent with other
reports that found that less or even no detectable antibodies did
not obliterate the ability of certain vaccine candidates to protect
in both avian [11,36,37] and mammalian [38,39] models.
It should also be pointed out that T-cell-dependent viral clear-
ance can induce bursal damage and delay follicle recovery [40],
which may be the cause of mild histopathological damage in BF.
M. Richetta et al. / Vaccine 35 (2017) 142–148 147Therefore, it can be thought that more viral particles reached the
bursa in those animals receiving homologous pVP2 or heterologous
rVP2/pVP2 schemes compared to chickens immunized with pVP2/
rVP2. However, further evaluations are needed to clarify the role of
the antigen sequence over the slight differences in protection
parameters.
Overall, the heterologous prime-boost approach did not show
clear evidence of being better than the homologous one. However,
the order in which the heterologous immunogens were delivered
was able to influence over the immune response, as the rVP2/
pVP2 scheme performed better when evaluated through humoral
immunity parameters, while pVP2/rVP2 was slightly better pre-
venting bursal damage. In a real field situation, an ideal prime
against IBDV should be able to surpass maternal antibodies at an
early stage – recombinant MVA may do this [41] and it has been
successfully used for in ovo vaccination [16] – and the boost should
be given with a highly immunogenic protein – as pVP2 – around
14 days after prime to achieve high levels of protection by the time
when chicks become more susceptible to the infection. In spite of
this, it remains unclear whether the humoral or the cellular branch
of the immune response is the most important against IBDV, but
this study is to be taken as a starting point to explore the mecha-
nisms through which recombinant MVA can enhance anti-IBDV
protective efficacy in the chicken.Conflict of interest
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